CN114306308A - Nutritional supplement containing ketoesters and application thereof - Google Patents
Nutritional supplement containing ketoesters and application thereof Download PDFInfo
- Publication number
- CN114306308A CN114306308A CN202111597532.4A CN202111597532A CN114306308A CN 114306308 A CN114306308 A CN 114306308A CN 202111597532 A CN202111597532 A CN 202111597532A CN 114306308 A CN114306308 A CN 114306308A
- Authority
- CN
- China
- Prior art keywords
- nutritional supplement
- parts
- ketoesters
- ketoester
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 55
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 9
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 5
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 5
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 5
- 235000015165 citric acid Nutrition 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000003931 cognitive performance Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (1R)-1,3-butanediol Natural products CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- PUPZLCDOIYMWBV-SCSAIBSYSA-N (R)-butane-1,3-diol Chemical compound C[C@@H](O)CCO PUPZLCDOIYMWBV-SCSAIBSYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 6
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 6
- 229920002079 Ellagic acid Polymers 0.000 claims description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960002852 ellagic acid Drugs 0.000 claims description 6
- 235000004132 ellagic acid Nutrition 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 6
- 235000019136 lipoic acid Nutrition 0.000 claims description 6
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 6
- 229960001285 quercetin Drugs 0.000 claims description 6
- 235000005875 quercetin Nutrition 0.000 claims description 6
- 229960002663 thioctic acid Drugs 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- -1 ethyl R-3-hydroxybutyrate Chemical compound 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 230000004140 ketosis Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 235000020887 ketogenic diet Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a nutritional supplement containing ketoester and application thereof, wherein the nutritional supplement comprises the following components in parts by weight: 20-50 parts of ketoester and 150-300 parts of medicinal carrier; the nutritional supplement is in liquid form; the medicinal carrier is one or any combination of citric acid, ascorbic acid, benzoic acid and lactate. The nutritional supplement is applied to a human subject at a dose of 2-4 mg/day, and is administered to the subject at least twice a day for at least 1 month or more, and has a display effect in the aspects of improving physical quality, cognitive ability and endurance.
Description
Technical Field
The invention relates to the technical field of chemical industry, in particular to a nutritional supplement containing ketoester and application thereof.
Background
Ketone esters, which are exogenous ketones, reach ketosis in humans soon after consumption of ketoesters. Ketosis is a state pursued by ketogenic diet, and in ketosis, a human body burns fat to generate energy, so that the human body does not feel hunger, and the cognitive ability of the human body is clearer. Ketosis is a state of nature of the human body and is often produced when ancient food is insufficient. In recent times, the body produces few cases because of the abundance of food. Meanwhile, because the carbohydrate is relatively abundant, a series of metabolic problems are generated.
In addition, several related studies using ketoesters have demonstrated that ketoesters can bring a variety of benefits: improving vascular endothelial function, improving oxidative stress and mitochondrial function, improving inflammation, promoting cardiac remodeling, and improving cardiovascular risk factors including blood pressure, body weight, blood glucose and blood lipid.
Therefore, the nutritional supplement containing the ketoester and the application thereof are provided, and the nutritional supplement has important significance for application and popularization.
Disclosure of Invention
In view of the above, the present application aims to provide a nutritional supplement containing ketoesters and its application, so as to expand the application thereof.
In order to achieve the above object, the present application provides the following technical solutions.
The first technical scheme is as follows: a nutritional supplement containing ketoesters comprises the following components in parts by weight: 20-50 parts of ketoester and 150-300 parts of medicinal carrier; the nutritional supplement is in liquid form.
Preferably, the nutritional supplement containing the ketoester comprises the following components in parts by weight: 30-40 parts of ketoester and 200-250 parts of medicinal carrier.
Preferably, the pharmaceutically acceptable carrier is one or any combination of citric acid, ascorbic acid, benzoic acid and lactate.
Preferably, the medicinal carrier is one or any combination of benzoic acid, glycerol, propylene glycol and polyethylene glycol.
Preferably, the pharmaceutically acceptable carrier is one or any combination of potassium hydroxide, sodium bicarbonate, calcium carbonate, silicon dioxide and magnesium aluminum silicate.
Preferably, the nutritional supplement further comprises an antioxidant, wherein the antioxidant is one or any combination of ellagic acid, quercetin, lipoic acid and vitamin C.
Preferably, the synthesis method of the ketoester is characterized in that the ketoester is synthesized by the enzymatic synthesis of R-3-hydroxy ethyl butyrate and (R) - (-) -1, 3-butanediol according to the proportion.
The second technical scheme is as follows: use of a nutritional supplement comprising ketoesters for improving physical fitness, cognitive performance and endurance in a human subject, said nutritional supplement being administered to said human subject at a dosage of 2-4 mg/day.
Preferably, the nutritional supplement is administered to the subject at least twice daily for at least 1 month or more.
The beneficial technical effects obtained by the invention are as follows:
the nutritional supplement comprises the following components in parts by weight: 20-50 parts of ketoester and 150-300 parts of medicinal carrier; the nutritional supplement is one of a tablet and a capsule; the nutritional supplement is administered to a human subject at a dosage of 2-4 mg/day for a period of time, and has shown effects in improving physical fitness, cognitive ability and endurance.
The foregoing description is only an overview of the technical solutions of the present application, and in order to make the technical means of the present application more clearly understood and to make the same practical in accordance with the content of the present specification, and to make the above and other objects, features, and advantages of the present application more apparent and understandable, preferred embodiments of the present application are described below in detail.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application are clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present application, but not all of the embodiments. In the following description, specific details such as specific configurations and components are provided only to help the embodiments of the present application be fully understood. Accordingly, it will be apparent to those skilled in the art that various changes and modifications may be made to the embodiments described herein without departing from the scope and spirit of the present application. In addition, descriptions of well-known functions and constructions are omitted in the embodiments for clarity and conciseness.
It should be appreciated that reference throughout this specification to "one embodiment" or "the embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present application. Thus, the appearances of the phrase "one embodiment" or "the present embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
Further, the present application may repeat reference numerals and/or letters in the various examples. This repetition is for the purpose of simplicity and clarity and does not in itself dictate a relationship between the various embodiments and/or configurations discussed.
The term "and/or" herein is merely an association describing an associated object, meaning that three relationships may exist, e.g., a and/or B, may mean: a exists alone, B exists alone, and A and B exist at the same time, and the term "/and" is used herein to describe another association object relationship, which means that two relationships may exist, for example, A/and B, may mean: a alone, and both a and B alone, and further, the character "/" in this document generally means that the former and latter associated objects are in an "or" relationship.
The term "at least one" herein is merely an association relationship describing an associated object, and means that there may be three relationships, for example, at least one of a and B, may mean: a exists alone, A and B exist simultaneously, and B exists alone.
It is further noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion.
Example 1
A nutritional supplement containing ketoesters comprises the following components in parts by weight: 20 parts of ketoester and 150 parts of medicinal carrier; the nutritional supplement is in liquid form.
The medicinal carrier is one or any combination of citric acid, ascorbic acid, benzoic acid and lactate.
The nutritional supplement further comprises an antioxidant, wherein the antioxidant is one or any combination of ellagic acid, quercetin, lipoic acid, and vitamin C.
The synthesis method of the ketoester is characterized in that the ketoester is synthesized by the enzyme catalysis of R-3-hydroxy ethyl butyrate and (R) - (-) -1, 3-butanediol according to the proportion.
The use of a nutritional supplement comprising ketoesters as described above in a medicament for improving physical fitness, cognitive performance and endurance, the nutritional supplement being administered to a human subject at a dosage of 2-4 mg/day.
Further, the nutritional supplement is administered to the subject at least twice daily for at least 1 month or more.
Example 2
A nutritional supplement containing ketoesters comprises the following components in parts by weight: 35 parts of ketoester and 220 parts of medicinal carrier; the nutritional supplement is in liquid form.
The medicinal carrier is one or any combination of benzoic acid, glycerol, propylene glycol and polyethylene glycol.
The nutritional supplement further comprises an antioxidant, wherein the antioxidant is one or any combination of ellagic acid, quercetin, lipoic acid, and vitamin C.
The synthesis method of the ketoester is characterized in that the ketoester is synthesized by the enzyme catalysis of R-3-hydroxy ethyl butyrate and (R) - (-) -1, 3-butanediol according to the proportion.
The use of a nutritional supplement comprising ketoesters as described above in a medicament for improving physical fitness, cognitive performance and endurance, the nutritional supplement being administered to a human subject at a dosage of 2-4 mg/day.
Further, the nutritional supplement is administered to the subject at least twice daily for at least 1 month or more.
Example 3
A nutritional supplement containing ketoesters comprises the following components in parts by weight: 50 parts of ketoester and 300 parts of medicinal carrier; the nutritional supplement is in liquid form.
The medicinal carrier is one or any combination of potassium hydroxide, sodium bicarbonate, calcium carbonate, silicon dioxide and magnesium aluminum silicate.
The nutritional supplement further comprises an antioxidant, wherein the antioxidant is one or any combination of ellagic acid, quercetin, lipoic acid, and vitamin C.
The synthesis method of the ketoester is characterized in that the ketoester is synthesized by the enzyme catalysis of R-3-hydroxy ethyl butyrate and (R) - (-) -1, 3-butanediol according to the proportion.
The use of a nutritional supplement comprising ketoesters as described above in a medicament for improving physical fitness, cognitive performance and endurance, the nutritional supplement being administered to a human subject at a dosage of 2-4 mg/day.
Further, the nutritional supplement is administered to the subject at least twice daily for at least 1 month or more.
Example 4
A nutritional supplement containing ketoesters comprises the following components in parts by weight: 30-40 parts of ketoester and 200-250 parts of medicinal carrier.
The medicinal carrier is one or any combination of citric acid, ascorbic acid, benzoic acid and lactate.
Alternatively, the pharmaceutically acceptable carrier is one or any combination of benzoic acid, glycerol, propylene glycol and polyethylene glycol.
Alternatively, the pharmaceutically acceptable carrier is one or any combination of potassium hydroxide, sodium bicarbonate, calcium carbonate, silica, and magnesium aluminum silicate.
The nutritional supplement further comprises an antioxidant, wherein the antioxidant is one or any combination of ellagic acid, quercetin, lipoic acid, and vitamin C.
The synthesis method of the ketoester is characterized in that the ketoester is synthesized by the enzyme catalysis of R-3-hydroxy ethyl butyrate and (R) - (-) -1, 3-butanediol according to the proportion.
The use of a nutritional supplement comprising ketoesters as described above in a medicament for improving physical fitness, cognitive performance and endurance, the nutritional supplement being administered to a human subject at a dosage of 2-4 mg/day.
Further, the nutritional supplement is administered to the subject at least twice daily for at least 1 month or more.
The above description is only a preferred embodiment of the present invention, and it is not intended to limit the scope of the present invention, and it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention. Variations, modifications, substitutions, integrations and parameter changes of the embodiments may be made without departing from the principle and spirit of the invention, which may be within the spirit and principle of the invention, by conventional substitution or may realize the same function.
Claims (9)
1. A nutritional supplement containing ketoesters is characterized by comprising the following components in parts by weight: 20-50 parts of ketoester and 150-300 parts of medicinal carrier; the nutritional supplement is in liquid form.
2. The nutritional supplement containing ketoesters according to claim 1, comprising the following components in parts by weight: 30-40 parts of ketoester and 200-250 parts of medicinal carrier.
3. The nutritional supplement according to claim 1 or 2, wherein the pharmaceutically acceptable carrier is one or any combination of citric acid, ascorbic acid, benzoic acid, lactate.
4. The nutritional supplement containing ketoesters according to claim 1 or 2 wherein the pharmaceutically acceptable carrier is one or any combination of benzoic acid, glycerol, propylene glycol, polyethylene glycol.
5. The nutritional supplement of claim 1 or 2, wherein the pharmaceutically acceptable carrier is one or any combination of potassium hydroxide, sodium bicarbonate, calcium carbonate, silica, magnesium aluminum silicate.
6. A nutritional supplement containing ketoesters according to claim 1 or 2 further comprising an antioxidant which is one or any combination of ellagic acid, quercetin, lipoic acid, vitamin C.
7. The nutritional supplement according to claim 1 or 2, wherein the ketoester is synthesized by enzymatic synthesis from ethyl R-3-hydroxybutyrate and (R) - (-) -1, 3-butanediol in the ratio.
8. Use of a nutritional supplement comprising ketoesters for improving physical fitness, cognitive performance and endurance performance in a medicament according to any one of claims 1 to 7, wherein the nutritional supplement is administered to a human subject at a dose of 2 to 4 mg/day.
9. Use of a nutritional supplement containing ketoesters in a medicament for enhancing physical fitness, cognitive performance and endurance as claimed in claim 8, wherein the nutritional supplement is administered to a subject at least twice daily for at least 1 month or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111597532.4A CN114306308A (en) | 2021-12-24 | 2021-12-24 | Nutritional supplement containing ketoesters and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111597532.4A CN114306308A (en) | 2021-12-24 | 2021-12-24 | Nutritional supplement containing ketoesters and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114306308A true CN114306308A (en) | 2022-04-12 |
Family
ID=81013557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111597532.4A Pending CN114306308A (en) | 2021-12-24 | 2021-12-24 | Nutritional supplement containing ketoesters and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114306308A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105050594A (en) * | 2013-03-19 | 2015-11-11 | 南佛罗里达大学 | Compositions and methods for producing elevated and sustained ketosis |
| US20200222353A1 (en) * | 2019-01-14 | 2020-07-16 | Christopher David Thompson | Ketone ester and ketone salt compositions and methods for using the same |
-
2021
- 2021-12-24 CN CN202111597532.4A patent/CN114306308A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105050594A (en) * | 2013-03-19 | 2015-11-11 | 南佛罗里达大学 | Compositions and methods for producing elevated and sustained ketosis |
| US20200222353A1 (en) * | 2019-01-14 | 2020-07-16 | Christopher David Thompson | Ketone ester and ketone salt compositions and methods for using the same |
Non-Patent Citations (1)
| Title |
|---|
| 王广兰等: "《运动营养学》", 华中科技大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW491693B (en) | Nutritive composition for cardiovascular health | |
| EP1720610B1 (en) | Alcohol metabolism moderating composition | |
| CA2529735A1 (en) | Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities | |
| RU2009128213A (en) | APPLICATION OF XANTHOGUMOL AND ISOXANTOGUMOL AS AN ACTIVE SUBSTANCE FOR PREVENTION AND / OR PREVENTION OF LIVER DISEASES | |
| JP4492956B2 (en) | Fermented acerola | |
| JP5843169B2 (en) | Fructose absorption inhibitor | |
| CN101485440A (en) | Method for producing ion release type gelating product for sobering-up and inhibiting food ingredient absorption and product | |
| CN114306308A (en) | Nutritional supplement containing ketoesters and application thereof | |
| JP2007517761A (en) | Anti-aging composition | |
| JP4981442B2 (en) | Anti-fatigue composition | |
| CN101766590B (en) | Combination for protecting peroxide injury of myocardium | |
| JP2019059761A (en) | Compositions for improving skin | |
| CN104922160A (en) | Composition prepared by compounding statin with Omega-3 fatty acid and coenzyme Q10 and application of composition | |
| US20080160001A1 (en) | Antihypercholesterolemic Formulation with Less Side-Effects | |
| US20140045904A1 (en) | Niacin formulations and methods with reduced flushing side effect | |
| CN109090585A (en) | One kind relieves the effect of alcohol, protect stomach, protect liver, shield brain composition and preparation method thereof | |
| CN104286855A (en) | Antrodia camphorata health product and use thereof | |
| JP6165586B2 (en) | Oral composition | |
| JP6220792B2 (en) | Blood acetaldehyde reducing agent | |
| CN108904807A (en) | Melbine complex composition and its application | |
| US8613963B2 (en) | Nutritional supplement | |
| WO1997033599A1 (en) | Fish oil and garlic nutritive composition | |
| See et al. | A comprehensive review and recent advances of vitamin C: Overview, functions, sources, applications, market survey and processes | |
| CN103798899A (en) | Weight-losing beverage and preparation method thereof | |
| JP7515849B2 (en) | Medicines or foods and beverages containing health-promoting compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220412 |
|
| RJ01 | Rejection of invention patent application after publication |